Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label and Single-center Phase IIa Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 DNA Vaccine (ICCOV) in Healthy Subjects Aged 18-75 Years

NCT05904054 is registered in ClinicalTrials.gov with Immuno Cure 3 Limited as lead sponsor.

NCT NCT05904054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05904054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label and Single-center Phase IIa Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 DNA Vaccine (ICCOV) in Healthy Subjects Aged 18-75 Years
Lead sponsor
Immuno Cure 3 Limited
Phase
Phase 2
Overall status
Completed
Start date
June 15, 2023
Completion date
May 31, 2024
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19